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Background. Cryptoccocal meningitis (CM) remains prevalent in HIV-infected individuals across South Africa (SA). Early 
diagnosis and management, aided by the existing Southern African HIV Clinicians Society (SAHIVSoc) 2007 guidelines on 
management of CM, could reduce the mortality associated with this condition. 
Objective. To review the management of adult patients with CM and adherence to the SAHIVSoc 2007 guidelines in a district hospital.
Methods. A retrospective chart review of patients admitted with CM from December 2011 to May 2012 was performed. The 
following key recommendations of the guidelines were evaluated: measurement of cerebrospinal fluid (CSF) opening pressure at 
the first lumbar puncture (LP), prescription of amphotericin B (AMB)/fluconazole therapy, intravenous prehydration preceding 
administration of AMB, monitoring of renal function and performance of serial LPs to manage raised intracranial pressure (ICP).
Results. A total of 57 patient charts were reviewed, of which 40 (70%) were of females. The mean age (range) of the cohort was 
36 (21 - 60) years. Fifty-two (91%) patients presented with headache. Confusion was recorded in 30 (53%) and vomiting in 26 
(46%). The major signs observed were fever (n=29 (51%)) and neck stiffness (n=34 (60%)). Fifty-five (96%) patients were HIV-
infected at presentation, with a median (range) CD4+ count of 77 (13 - 90) cells/µl. None of the patients had a CSF opening 
pressure measured at first LP. AMB was used as an induction agent in 51 (89%) patients, of whom 47 (92%) completed 2 weeks 
of AMB. Of these 51, only 20 (40%) were prehydrated and 10 (18%) had two repeat LPs performed 1 week apart. Renal function 
was monitored in only 27 (53%) of the patients receiving AMB. This was done at baseline and twice weekly, and was consistent 
with the guidelines. No abnormality in renal function was recorded in these cases during the study. The mortality rate was 30% 
in the first 10 days of admission.
Conclusion. This chart review showed inadequate adherence to the recommendations of the 2007 SAHIVSoc guidelines in the 
majority of cases except for the use of AMB as a first-line antifungal agent. Control of ICP and monitoring for drug toxicity were 
not done as per guidelines and may impact on clinical care and outcome. Despite this, the early 30% mortality is comparable 
with published reports from other regions in SA, but is higher than in developed health systems. 
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Worldwide, the burden of cryptoccocal menin-
gitis (CM) is estimated to be 0.04 - 12% per year 
among persons with HIV, resulting in nearly 
625 000 deaths.[1] Sub-Saharan Africa has the 
highest yearly burden with 720 000 cases (range 
144 000 - 1.3 million).[1] In sub-Saharan Africa, mortality is 
estimated to be 50 - 70%, compared with 12% in the USA and 
other developed nations.[2] Cryptococcus neoformans infections are 
very rare in healthy people, with a yearly incidence of 0.4 - 1.3 cases 
per 100 000 in the general population.[2] In a population-based 
surveillance of cryptococcosis in Gauteng, South Africa (SA), the 
overall incidence rate was 15.6/100 000 among both HIV-positive 
and -negative individuals.[3] Among HIV-positive persons, the rate 
was 95/100 000, and among persons living with AIDS, 14/1 000.[3] 
In HIV-positive individuals, CM may present with headaches, 
unexplained fever, nausea, vomiting, neck stiffness, confusion, 
seizures, abnormal behaviour, and new onset of psychiatric 
symptoms, altered level of consciousness, focal neurological signs, 
diplopia, unexplained blindness and sometimes coma.[4] Headache 
is the predominant symptom and was observed in 100% of cases 
in a study done by Baradkar et al.[5] Neck stiffness may be absent 
in some patients with CM.[6] The presentation of CM may be acute, 
sub-acute (over 2 - 4 weeks), or chronic (>4 weeks).[4] 
Despite the availability of highly active antiretroviral treatment 
(HAART), the mortality from CM has not changed from 
the pre-HAART era. However, CM immune reconstitution 
inflammatory syndrome (IRIS) is implicated in the ongoing high 
mortality.[7] It is also not uncommon to have other opportunistic 
infections together with CM that contribute to mortality.[8]
Elevated intracranial pressure (ICP) results in increased 
mortality and morbidity. Up to 40% of CM deaths occurring 
during weeks 3 - 10 of treatment were associated with elevated ICP. 
Visual loss was also observed as a consequence of elevated ICP.[9]
A high index of suspicion is needed for the diagnosis of CM, 
especially in sub-Saharan Africa, where there is a dearth of 
standard laboratory facilities and expertise. Therefore, the role 
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of a detailed history and physical examination 
cannot be overemphasised.[10] The definitive 
diagnosis involves cerebrospinal fluid (CSF) 
microscopy, cryptococcal antigen (CrAG) 
detection in CSF and/or serum, and the culture 
of C. neoformans.[11] If an Indian ink stain is 
negative, CrAG remains a reliable test (95% 
sensitivity, 95% specificity). The CrAG Latex 
Agglutination System (Meridien Bioscience, 
US) is commonly used and correlates well 
with the fungal burden.[11]
In a retrospective study conducted in Durban, 
SA, the significantly higher Indian ink positivity 
rate and significantly higher mean CrAG titre 
reflected the greater fungal load in HIV-positive 
patients.[12] Culture of C. neoformans in CSF is 
also beneficial in the diagnosis of subsequent 
episodes of CM where both CrAG and Indian 
ink tests are not useful.[13] 
The only guideline for the management of 
CM in our setting, prior to 2012 when this study 
was conducted, was published by the SAHIVSoc 
in 2007.[6] This guideline was updated in 2013. 
The initial guideline highlighted the role of 
amphotericin B (AMB) as the antifungal 
agent preferred during the induction phase of 
treatment. Treatment with AMB (1 mg/kg body 
weight (BW)/day) for 2 weeks, followed by 
fluconazole (400 mg/day) as a consolidation 
agent for 8 weeks was recommended. A dose 
of 200 mg fluconazole daily is indicated 
for secondary prophylaxis until the CD4+ 
T-lymphocyte count is >200 cells/µl for at least 
6 months and the most recent HIV-1 viral load 
is suppressed; this applies to patients with a first 
episode of CM.[6] Patients with relapse are treated 
with 1 mg/kg BW AMB for 2 - 4 weeks or until 
the CSF is sterile. Consolidation and maintenance 
options in relapse depend on the fluconazole 
minimum inhibitory concentration and include 
high-dose fluconazole with or without weekly 
AMB infusions, or voriconazole. [6]
AMB is often unavailable in our centres, hence 
high-dose fluconazole (800 - 1 200 mg) is often 
used. The latter is suboptimal at these doses.
[14] For resource-limited settings where AMB is 
unavailable, high-dose fluconazole (1 200 mg) 
is recommended as an induction agent by the 
World Health Organization (WHO).[15]
Similar to the SAHIVSoc guidelines, 
Tronconso et al.[16] highlighted the role of 
monitoring renal function while patients are 
undergoing the induction phase with AMB. 
If creatinine increases by twofold, the AMB 
dose is omitted and prehydration with 0.9% 
normal saline, 1 l 8-hourly, is recommended. 
AMB should be stopped if the creatinine fails to 
decrease after this intervention.[6]
In June 2013, the SAHIVSoc updated the 
guideline for the prevention, diagnosis and 
management of CM in HIV-positive persons 
to be compatible with WHO guidelines. A 
major change from the 2007 version is the 
role of both AMB and fluconazole during the 
induction phase. The revision also highlighted 
timing of HAART initiation.[13]
Methods
The study was a descriptive, retrospective 
chart review conducted at the Mthatha 
General Hospital in the Eastern Cape (EC), 
SA, between December 2011 and May 2012. 
The majority of patients with CM in the OR 
Tambo district of the EC are managed as 
inpatients in this facility. The hospital serves 
as a referral centre and has 100 medical beds.
The inclusion criteria were adult patients 
>18 years of age with a first episode of CM 
diagnosed on lumbar puncture (LP) as part of 
routine care of patients with clinical features of 
meningitis. Patients were managed by a team 
of doctors that included an intern, medical 
officer/registrar and a family physician. The 
researcher did not interact with the patients.
For data collection, a researcher searched 
the ward register daily for cases diagnosed 
as CM and admitted to any of the medical 
wards. Data were collected from respective 
patient case note files. The medical records of 
all patients identified with CM from the ward 
register were available for data collection and 
were verified by positive laboratory results. 
The data of interest were: measurements of 
CSF opening pressure at the first LP; whether 
AMB/fluconazole therapy was used; whether 
prehydration was administered before the receipt 
of AMB; and whether monitoring of renal 
function (rising urea and creatinine only) and 
ICP were done according to the recommen-
dations of the SAHIVSoc 2007 CM guidelines.
The time of commencement of AMB was 
documented in the prescription/drug chart 
of each patient and the time of admission 
was recorded on the admission chart and 
the nurses’ charts. The renal function of each 
patient was determined from the laboratory 
report in the case notes. 
Data were analysed using SPSS version 
18.0 (IBM, South Africa). Descriptive data 
were presented using frequency tables. Ethical 
approval was obtained from the Biomedical 
Research Ethics Committee of the University of 
KwaZulu-Natal (number BE058/12). 
Results
A total of 57 charts were reviewed over 
the 6-month study period, representing all 
patients who were admitted to the medical 
wards with CM in this time period. However, 
some patients may have died in casualty before 
ward admission and hence would not have 
been captured in the ward admission charts. 
The mean age (range) of the patients was 
36 (21 - 60) years, and 40 were women (70%).
Table 1 shows the presenting complaints, signs 
and their frequency of occurrence. Of the 
57 patients, 52 (91%) presented with headache. 
Confusion was recorded in 30 (53%) and 
vomiting in 26 (46%) of subjects. The major 
signs observed were fever in 29 (51%), and 
meningeal signs in 34 (60%).
All patients had an initial LP for CSF 
laboratory analysis that included biochemistry, 
Indian ink stain, CrAG assay and fungal 
culture. A computerised tomography (CT) 
scan was done in only two patients with 
Table 1. Presenting symptoms and signs of patients admitted with 
cryptococcal meningitis (N=57)
Presenting complaints n %
Headache 52 91
Confusion 30 53





Neck stiffness 34 60
Kernig’s and Brudzinski’s signs 34 60
Focal signs (hemiparesis) 1 2












106    SAJHIVMED   SEPTEMBER 2014, Vol. 15, No. 3 
focal signs and cranial nerve deficits, showing 
a mass lesion in both cases, suggestive of 
cryptococcoma. There was no record of the 
measurement of CSF opening pressure at LP 
in any of the charts reviewed. The diagnosis of 
CM was made within 24 hours of presentation 
(range 3 - 8 hours) in 70% of the patients. 
This was calculated from the time the LP was 
performed to the time the microscopy result 
was obtained. All 57 cases were positive for 
microscopy and culture for C. neoformans, 
while CrAG was positive in 51 (89%) cases. 
HIV infection was diagnosed for the first 
time in 7 (12%) of these patients. The remain-
ing 50 (88%) were known to be HIV-positive. 
All had features of immunosuppression. The 
most frequent infections were oropharyngeal 
candidiasis and tuberculosis (TB) (Table 2). 
The median (range) CD4+ count was 77 (51 - 
100) cells/µl. Twenty-two (39%) of the 57 patients 
were on HAART. Thirteen (23%) patients had 
been on ARVs for less than 6 months and the 
remaining 9 (16%) patients had been on ARVs 
for 7 - 12 months. All patients were on tenofovir, 
lamivudine and efavirenz and were documented 
to be adherent to treatment. Tenofovir was 
continued even when AMB was commenced.
Thirty-two (56%) of the patients had 
co-infection with pulmonary TB. Ten of 
these patients were diagnosed on sputum 
microscopy for acid-fast bacilli, while the 
remainder were diagnosed clinically and 
on chest radiography. Ten patients had 
tuberculous meningitis co-infection based on 
CSF lymphocytosis and raised protein.
AMB (1 mg/kg BW) was used as the induction 
agent for the management of CM in 51 (89%) 
of the patients, while the remaining 6 (11%) had 
intravenous fluconazole (800 mg) because AMB 
was out of stock. Among the 51 patients who 
had AMB as an induction agent, the drug was 
initiated in 50 (98%) cases, within 24 hours of 
the attending doctor writing the script. The time 
of commencement of AMB was documented 
in the prescription/drug chart by the nurse 
administering the dose and the time of admission 
was recorded on the patient chart. Only 20 (39%) 
patients receiving AMB had documentation 
of adequate prehydration. Forty-seven (92%) 
patients completed the 2-week course of AMB. 
Renal function was monitored in 27 (53%) 
of the patients receiving AMB. This was done at 
baseline and twice weekly, and was consistent 
with the guideline. Results were obtained from 
the case files and the normal ranges for urea 
and creatinine were 2.1 - 7.1 mmol/l and 64 - 
104 µmol/l, respectively. No abnormalities in 
serum urea and creatinine were recorded in 
these cases during the study.
Ten patients (18%) who experienced 
worsening headache in the ward had two repeat 
LPs performed for the management of raised 
ICP. These LPs were performed 1 week apart. 
Forty patients (70%) were discharged, with 
the average (range) hospital stay being 21 (16 - 
28) days. The in-hospital mortality rate within 
the first 1 - 10 days of hospital admission 
was 30%. Fluconazole 400 mg was dispensed 
on discharge for 1 week of the consolidation 
phase and patients were referred to a local 
clinic to continue treatment. Data on patients 
prescribed HAART were not obtained.
Discussion
There are few data on management and 
outcome of CM from a non-research district 
hospital setting in a resource-limited health 
system where operational challenges may have 
a significant impact. This study was limited by 
the retrospective, descriptive nature. Although 
all patient charts were found, documentation 
in the clinical notes was poor and missing data 
compromised this chart review.
The Mthatha complex manages 6 - 10 cases 
of CM in AIDS patients per month. Some cases 
of CM could have been missed in this review 
if patients died in casualty and hence were 
not captured in the ward admission file. This 
retrospective chart review of adult patients found 
that the management was not consistently in line 
with national guidelines. Unlike other studies 
where the incidence of CM was similar in both 
sexes, or higher in men,[1] we found that the 
disease was three times higher in women. The 
reason for this may be the migrant nature and 
different health-seeking behaviour of men in this 
community and warrants further investigation. All 
patients were HIV-positive with a median CD4+ 
count of 77 cells/µl, consistent with the results 
in other studies. [1,3] An interesting observation is 
that 88% of patients were known to be infected 
with HIV prior to the diagnosis of CM. The 
mortality of 30% was less than that reported in a 
Ugandan study in a similar patient population 
and healthcare system, where mortality was 
between 40% and 50%.[7] The mortality was 
similar to that in other centres in SA.[17]
Many patients already diagnosed with HIV 
infection were not on ARVs at the time of 
presentation. This is of concern as it is likely 
that CM may have been preventable in the 
majority. This observation highlights the need 
for a more intensive rollout of ARV treatment. 
Our study also highlighted the occurrence 
of CM in the first 6 months of HAART, 
which may represent IRIS or reflect ongoing 
immunosuppression during early HAART.
Headache was the most common symptom. 
Vomiting, fever, confusion and psychosis 
were also noted. However, meningeal signs 
were absent in 40% of the patients. This 
may be owing to poor inflammatory response 
attributed to severe immunosuppression. 
The study found that co-infections, 
particularly TB, were extremely high in these 
CM patients. This is not surprising, because 
of profound immunosuppression and the high 
prevalence of TB in our setting. Many cases of 
TB were diagnosed on clinical or radiological 
features, or suggestive CSF microscopy and 
biochemistry. Since these are not specific 
diagnostic tests, overdiagnosis of TB was possible. 
The CSF CrAG was found to be an extremely 
important test; 77% of the patients were 
diagnosed within 24 hours of presentation using 
this assay. The CrAG test should be routinely 
performed by the laboratory if the India ink 
stain is negative. The effect of early diagnosis on 
morbidity and mortality is well documented. [18] It 
was also demonstrated that patients who presented 
with features of neurological deficit received a 
CT scan as recommended by the guideline.[6] 
None of the patients admitted had an opening 
CSF pressure measured during the LP and 
fundoscopy was not done, which is of concern. 
Documentation and management of ICP was 
also not done. This was presumably because the 
hospital does not stock manometers.
Drug treatment aspects of the 2007 
SAHIVSoc guidelines were followed in most 
Table 2. Concurrent opportunistic infections and comorbidities in 
patients with cryptococcal meningitis (N=57)
Opportunistic infections n %
Pulmonary tuberculosis 32 56
Oropharyngeal candidiasis 57 100
Seborrhoeic dermatitis 12 21
Oral hairy leukoplakia 8 14
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patients who received AMB as the induction agent, and all were 
discharged on fluconazole, 400 mg daily, as a consolidation agent.[6]
Prehydration and renal toxicity monitoring advised by the guideline 
were not followed, and it is surprising that more renal complications 
were not observed. However, documentation of fluid administration 
is poor in our facility. Early mortality rates may have improved if these 
measures had been implemented.
Conclusion
We recommend that an in-service workshop on common opportunistic 
infections in HIV should be provided for healthcare providers within 
the district hospital setting. A commitment by the Department of 
Health to provide necessary diagnostic tools, including manometers, 
and an uninterrupted drug supply would improve the management and 
outcome of the disease at a district level. 
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